TABLE 4.
Results of a logistic regression analysis of the factors associated with e‐PD.
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
| Age (≥75 years) | 1.6 (0.80–3.0) | 0.18 | ||
| Etiology (nonviral) | 0.9 (0.48–1.8) | 0.83 | ||
| Performance status (≥1) | 4.9 (2.3–10) | <0.001 | 4.5 (1.9–10) | <0.001 |
| ALBI score (≥−2.30) | 2.6 (1.3–5.1) | 0.006 | 2.1 (1.0–4.5) | 0.044 |
| Tumor size (≥30 mm) | 1.4 (0.68–2.8) | 0.37 | ||
| Tumor number (>3) | 1.3 (0.60–2.64) | 0.54 | ||
| Macrovascular invasion (present) | 1.6 (0.72–3.7) | 0.23 | ||
| Main portal vein invasion (present) | 1.7 (0.53–4.3) | 0.23 | ||
| Extrahepatic metastasis (present) | 1.6 (0.82–3.3) | 0.16 | ||
| BCLC (C) | 2.3 (1.1–4.8) | 0.029 | 1.3 (0.56–3.0) | 0.54 |
| AFP (≥400 ng/mL) | 1.3 (0.62–2.6) | 0.52 | ||
| AFP‐L3 (≥25%) | 1.1 (0.51–2.2) | 0.89 | ||
| DCP (≥400 mAU/mL) | 1.6 (0.83–3.2) | 0.15 | ||
| AE within 9 weeks (present) | 0.9 (0.39–1.9) | 0.68 | ||
| Reduction or withdrawal of bevacizumab within 9 weeks (present) | 1.1 (0.37–3.3) | 0.85 | ||
| Systemic therapy (present) | 3.1 (1.6–6.2) | 0.001 | 3.0 (1.4–6.4) | 0.003 |
Abbreviations: AE, adverse event; AFP, alpha‐fetoprotein; AFP‐L3, LCA‐reactive alpha‐fetoprotein isoform; ALBI, albumin–bilirubin; CI, confidence interval; DCP, des‐gamma‐carboxy prothrombin.